Anaptysbio Inc - ANAB STOCK NEWS

AnaptysBio announced positive results from the PERLA Phase 2 trial, comparing JEMPERLI against Keytruda in metastatic non-squamous lung cancer, achieving its primary endpoint of objective response rate (ORR). Additionally, the COSTAR trial, evaluating JEMPERLI in combination with cobolimab, met its pre-specified efficacy and safety criteria, allowing progression to Phase 3. AnaptysBio expects to receive a $5 million milestone payment from GSK upon dosing the first patient in the Phase 3 COSTAR trial. JEMPERLI is being developed for various advanced cancers, while cobolimab is an investigational TIM-3 antagonist.

AnaptysBio, a clinical-stage biotechnology company, announced the sale of its royalty interest in Zejula to DRI Healthcare Trust for up to $45 million. The company received an upfront payment of $35 million for a 1% royalty on global net sales, which is effectively 0.5% due to third-party royalties. AnaptysBio stands to gain an additional $10 million contingent upon FDA approval of Zejula for endometrial cancer, expected by December 31, 2025. This sale supports their focus on innovative immunology therapeutics.

AnaptysBio announced disappointing results from its HARP Phase 2 trial of imsidolimab, an anti-IL-36 receptor antagonist for hidradenitis suppurativa, which showed no significant efficacy over placebo in primary and key secondary endpoints. The company will discontinue this clinical development but continues to enroll patients in the GEMINI-1 Phase 3 trial for generalized pustular psoriasis (GPP), with top-line data expected in Q4 2023. AnaptysBio plans to outlicense imsidolimab prior to FDA approval and shift focus to its immune cell modulator pipeline, including two checkpoint agonists, rosnilimab and ANB032.

AnaptysBio (ANAB) reported Q2 2022 results, highlighting an operating cash position of $572.1 million, with anticipated net cash burn estimated at $90-$100 million for 2022.

Collaboration revenue fell significantly to $1.2 million compared to $30 million a year prior. Research and development expenses decreased to $20.8 million, while general and administrative costs increased to $8.2 million due to personnel changes. The company posted a net loss of $32.6 million for Q2, with a net loss per share of $1.15, up from a $0.4 million loss in Q2 2021.

AnaptysBio, a clinical-stage biotechnology firm, is set to participate in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 3:30 p.m. ET. CEO Dan Faga and CMO Paul Lizzul will represent the company. The presentation will be available via live audio webcast on AnaptysBio's investor website, with a replay accessible for 90 days post-event. AnaptysBio specializes in immunology therapeutics, with a focus on developing innovative treatments for inflammatory diseases, leveraging its proprietary antibody discovery platform.

AnaptysBio, a clinical-stage biotechnology company (Nasdaq: ANAB), announced that CEO Dan Faga and CMO Paul Lizzul will speak at the Jefferies Healthcare Conference on June 8, 2022, at 10:00 a.m. ET. A live audio webcast will be accessible on their investor website, with a replay available for 90 days.

The company develops first-in-class antibodies targeting inflammation and immuno-oncology. Their pipeline includes imsidolimab for dermatological conditions and rosnilimab for alopecia areata, among others, utilizing their proprietary somatic hypermutation platform for antibody discovery.

AnaptysBio reported its Q1 2022 financial results with cash reserves at approximately $596.8 million. The company anticipates key trial data releases: the GEMINI-1 Phase 3 trial for imsidolimab in generalized pustular psoriasis by Q4 2023, and top-line results from the HARP Phase 2 trial for hidradenitis suppurativa in Q3 2022. A decrease in collaboration revenue to $1.0 million was noted, down from $11.2 million in Q1 2021. R&D expenses decreased to $22.5 million, while G&A expenses surged to $10.2 million due to one-time costs. The net loss was $36.3 million, reflecting a per-share loss of $1.31.

AnaptysBio announced positive results from a Phase 1 trial of ANB032, a novel anti-BTLA agonist antibody. The trial demonstrated favorable safety and tolerability, with no serious adverse events. ANB032 showed a rapid and sustained pharmacokinetic profile, with a two-week half-life. The IND filing for a Phase 2 trial is expected in late 2022. Additionally, top-line data from the Phase 2 trial of Imsidolimab in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022, while GPP Phase 3 trial data is expected in Q4 2023.

AnaptysBio (Nasdaq: ANAB) announced the appointment of Daniel Faga as interim CEO following the resignation of Hamza Suria. Faga, who has extensive experience in the biopharmaceutical industry, aims to advance the company's three clinical-stage antibody programs. AnaptysBio is conducting a strategic portfolio review while focusing on ongoing clinical trials for its lead candidates, including imsidolimab, rosnilimab, and ANB032. The company reported having approximately $615 million in cash as of the end of 2021, which will support its development activities.